Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.63 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.63 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924358 | 0.91 | CYP4F2 (0.54) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL4113212 | 0.89 | CYP4F2 (0.76) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL8142270 | 0.82 | CYP4F2 (0.72) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL4104271 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL112297 | 0.81 | CYP4F2 (0.71) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL4613929 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL5546570 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL112488 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL1107142 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL7981410 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119822949-A | Method for synthesizing loxoprofen sodium by using resin catalyst | 烟台舜康生物科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119822949-A | Method for synthesizing loxoprofen sodium by using resin catalyst | 烟台舜康生物科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-115427405-B | Tricyclic compounds, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024083177-A1 | AROMATIC ACETYLENE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 浙江海正药业股份有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-113979893-B | N-hydroxy formamidine derivative, preparation method and application | 中国药科大学 | 2023-10-24 | — | — | CN | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-112094259-B | Iodine (III) -mediated radiofluorination | 通用医疗公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2000064866-A1 | DIPHENYLUREA DERIVATIVES | ASTRAZENECA AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
| US-5919793-A | QUINUCLIDINE DERIVATIVES, SQUALENE SYNTHETASE INHIBITORS, ANTICHOLESTEROL AGENTS | ZENECA LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| WO-1998045298-A1 | ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-15 | — | — | WO | disclosed |
| CN-1121718-A | Heterocyclic derivatives | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| EP-0696284-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025459-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| US-4537902-A | TREATMENT OF KIDNEY AND BLADDER STONES | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4168385-A | LOWERING OF STEROL AND TRIGLYCERIDE SERUM LEVELS | AMERICAN CYANAMID COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
| US-4125729-A | Hypolipemic α-aryloxy para substituted phenyl acetic acid compounds | AMERICAN CYANAMID COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | RIPK1, RIPK4, RIPK3 | CYP4F2 3721/4885CYP4A11 1660/4885HSP90AB1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.